Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   IMNP immunepharmaceuticals een pareltje!

BioPharma« Terug naar discussie overzicht

IMNP immunepharmaceuticals een pareltje!

Volgen
766 Posts
Pagina: «« 1 2 3 4 5 6 ... 39 »» | Laatste | Omlaag ↓
  1. Omnius 12 juli 2016 11:12
    www.prnewswire.com/news-releases/immu...

    The licensing of AmiKet® and AmiKet® Nano for the treatment of peripheral neuropathic pain to a newly-created pain specialty pharma company:
    Immune executed an exclusive 60-day option with Novel Pain Therapeutics ("NPT") to enter into a worldwide license agreement for AmiKet and AmiKet Nano for the treatment of peripheral neuropathic pain. Upon execution of the license agreement pursuant to agreed material terms in the option, NPT will assume all research and development costs and Immune will be eligible to receive up to $160 million, comprised of an upfront fee of at least $15 million in the form of equity in NPT, up to $25 million in development milestones, and up to $120 million in commercial milestones, as well as product sales royalties. Immune will also be eligible to receive 25% and up to 50% of sublicense fees received by NPT.

    NPT kan beter de hele toko kopen voor 50 miljoen, eruit halen wat ze willen hebben en de rest doorverkopen.
  2. [verwijderd] 12 juli 2016 12:17
    quote:

    Omnius schreef op 12 juli 2016 11:12:

    www.prnewswire.com/news-releases/immu...

    The licensing of AmiKet® and AmiKet® Nano for the treatment of peripheral neuropathic pain to a newly-created pain specialty pharma company:
    Immune executed an exclusive 60-day option with Novel Pain Therapeutics ("NPT") to enter into a worldwide license agreement for AmiKet and AmiKet Nano for the treatment of peripheral neuropathic pain. Upon execution of the license agreement pursuant to agreed material terms in the option, NPT will assume all research and development costs and Immune will be eligible to receive up to $160 million, comprised of an upfront fee of at least $15 million in the form of equity in NPT, up to $25 million in development milestones, and up to $120 million in commercial milestones, as well as product sales royalties. Immune will also be eligible to receive 25% and up to 50% of sublicense fees received by NPT.

    NPT kan beter de hele toko kopen voor 50 miljoen, eruit halen wat ze willen hebben en de rest doorverkopen.
    Klopt als een bus en daarom knalt hij nu door. Als NPT het zooitje overneemt dan kun je lachen.

    Desondanks zal iedere deal zeer bijzonder zijn.
  3. [verwijderd] 12 juli 2016 12:19
    quote:

    Omnius schreef op 12 juli 2016 10:50:

    had me nog niet echt hierin verdiept, maar zie dat ze een behoorlijke pijplijn hebben, en dat bij een marketcap van 20 milj. USD.

    zie dat ze bezig zijn met een deal voor Amiket:
    www.insiderfinancial.com/immune-pharm...

    The highlight of the recent update was that IMNP executed an exclusive 60-day option with Novel Pain Therapeutics (“NPT”) to enter into a worldwide license agreement for AmiKet and AmiKet Nano for the treatment of peripheral neuropathic pain. Upon execution of the license agreement pursuant to agreed material terms in the option, NPT will assume all research and development costs and Immune will be eligible to receive up to $160 million, comprised of an upfront fee of at least $15 million in the form of equity in NPT, up to $25 million in development milestones, and up to $120 million in commercial milestones, as well as product sales royalties. Immune will also be eligible to receive 25% and up to 50% of sublicense fees received by NPT.

    While the news is indeed positive, it’s still just a 60-day option and needs to be executed. That’s why shares ultimately sold off after the news was announced. The recent bounce has us thinking that the deal may be happening and some in the know are buying in anticipation of the option being executed. Shares also put in a triple bottom at $.20 per share and that signaled to momentum players to pile in and drive the shorts to cover their positions.

    Dit is dus de reden van de stijging van de laatste weken? Hopelijk slepen ze er een goede deal uit, zodat de cashproblemen opgelost zijn.
    Ze hebben genoeg om voor altijd uit de zorgen te zijn. Voor vrijdag zal er wel een mooie deal op tafel liggen. Tot die tijd genieten van de koersstijging want die is nog maar net begonnen.

    Ze komen immers nog niet zo lang geleden van 2$.

    Europa 15%+ dus dat ziet er voor Imnp notering USA goed uit. Benieuwd of er rond 14:00 een PB op tafel ligt.

    Succes man
  5. [verwijderd] 12 juli 2016 14:43
    quote:

    greenways schreef op 12 juli 2016 13:10:

    .53 nu, laat maar lekker gaan zo.
    Succes allen.
    precies, ziet er goed uit voor komende periode. hopelijk vallen ze nu niet meer terug en wordt er echt gezorgd voor een uitbraak! charts zien er goed uit en echt iedereen is Bullish.

    Nu nabeurs (wat meestal is met de europese notering) nog een mooi PB en morgen Fly high, plusje van 500% ofzo, wat voor Bio normaal is ;-)

    greets,
  7. [verwijderd] 12 juli 2016 20:49
    Vanmiddag toch even wat winst genomen op 0.52 en de helft weer op 0.497 teruggekocht om te laten staan voor de langere periode (tja dat ligt er aan hoor;).

    Succes iedereen, er zijn er vele positief op Yahoo forum en twitter.. Ben erg benieuwd of dit een originele pump en dump is.
    Er moet in iedergeval voor de 15e een bericht verschijnen mbt de "deal".

  10. [verwijderd] 13 juli 2016 12:03
    Mooi stukje Junkbond. Verwacht jij voor de 15e (vrijdag dus), een persbericht imv overeenkomt NPT?

    How Immune Is Positioning Itself In Immuno-Oncology
    Jul.12.16 | About: Immune Pharmaceuticals (IMNP) Get Alerts
    Immune Pharmaceuticals, Inc. Immune Pharmaceuticals, Inc.Follow(15 followers)
    Small-cap, biotech
    Send Message
    Summary

    We have a multi-pronged strategy in I/O.

    Recent post hoc analysis and biomarker data on Ceplene shows meaningful potential for the drug.

    Our Bi-specific and NanomAb platform holds significant potential for product development.

    By Dr. Daniel Teper (Chief Executive Officer), Dr. Monica E. Luchi, (EVP, Chief Medical Officer), and Dr. Miri Ben-Ami (President, Immune Oncology)

    Last week, on June 29th, hundreds of leaders across the health, academic, private industry, and philanthropic sectors joined together with patients, survivors, and advocates for a national summit - a Cancer Moonshot. A goal is to make exponential progress in the fight against cancer. Vice President Joseph Biden issued the challenge, "Make a decade-worth of progress in the next five years," and more than 6,000 people around the country came together for more than 270 local events in their communities to heed the call.

    We at Immune Pharmaceuticals (NASDAQ:IMNP) are pushing forward with a multi-pronged approach to fighting cancer. Over the past year, we have significantly expanded our immuno-oncology (I/O) senior leadership to drive this effort forward. Our efforts in I/O are headed up by Miri Ben-Ami, MD, a former senior executive at Teva, Monica Luchi, MD, with a track record of a successful clinical development at Novartis, Incyte and Mesoblast, Mark L. Levitt, MD, PhD a Board Certified Medical Oncologist, SVP, Clinical Affairs and Jean Kadouche, PhD, SVP, Scientific Development and the co-inventor of our bi-specific antibody platform. Additionally, our labs at the Alexandria Center in New York City are headed up by Boris Shor, Ph.D. Dr. Shor brings more than a decade of pharma industry experience in oncology drug discovery. He joined Immune from Pfizer Oncology Research Unit where he led internal and external collaboration project teams to develop novel antibody-drug conjugates (ADCs) for the treatment of cancer.

    We are also aggressively expanding our pipeline. Earlier in the year, we laid out plans for the I/O business unit, which centers around two late-stage assets, Ceplene® and Azixa®, and two novel technology platforms, bi-specifics and NanomAbs®. Over the past six months, we have made significant progress on all fronts.
  12. Omnius 13 juli 2016 16:40
    minder dagje vandaag, misschien door deze headline (die toch al bekend was?):
    www.journaltranscript.com/2016/07/imm...

    The NASDAQ has granted Immune Pharmaceuticals Inc (NASDAQ:IMNP) an additional 180 calendar days, to regain compliance with the Listing Rule 5810(c) (3). Under the rule, companies are expected to ensure their stock trades above the $1 a share mark, in the market. That has not been the case for the pharmaceutical company, which was handed its first warning at the start of the year.

    Should the company fail to comply by, January 3, 2017, it faces a possible delisting from the NASDAQ Capital Market.

    Patent Application

    Meanwhile, the clinical stage biopharmaceutical company has filed a patent application for the combination of AZIXA and Immune checkpoint inhibitors for the treatment of Cancer. The company on its filing says that the recent pre-clinical experiments have proved beyond doubt that the combination can cause improved tumor response.

    Chief executive officer, Dr. Daniel Teper, says that such combination treatments have the potential to augment response to immune checkpoint inhibitors. The executive expects the recent data to open up new potential strategic options, given that Azixa has already demonstrated pre-clinical trial and clinical activity in multiple tumor types.

    Expansion of Bertilimumab Phase II Trial

    Separately, Immune has confirmed the expansion of its Bertilimumab Phase II clinical trial to include six new clinical sites in the United States. The company has already received IRB approval for the use of the anti-eotaxin monoclonal antibody for the treatment of bullous pemphigoid.

    Bertilimumab bills itself as a first class anti-eotaxin able to block eotaxin-1, which is a key driver of the condition. Common in old people, the disease manifests itself with the blistering of the skin. There are currently about 60,000 people in the US and Europe struggling with the condition

    Some of the new sites where Immune Pharmaceuticals Inc (NASDAQ:IMNP) will carry out the trials include the, University Hospitals Cleveland Medical Center, Mount Sinai in New York, Duke University, the University of Iowa, the University of Buffalo, and the University of Utah.
  13. [verwijderd] 13 juli 2016 17:56
    quote:

    Omnius schreef op 13 juli 2016 16:40:

    minder dagje vandaag, misschien door deze headline (die toch al bekend was?):
    www.journaltranscript.com/2016/07/imm...

    The NASDAQ has granted Immune Pharmaceuticals Inc (NASDAQ:IMNP) an additional 180 calendar days, to regain compliance with the Listing Rule 5810(c) (3). Under the rule, companies are expected to ensure their stock trades above the $1 a share mark, in the market. That has not been the case for the pharmaceutical company, which was handed its first warning at the start of the year.

    Should the company fail to comply by, January 3, 2017, it faces a possible delisting from the NASDAQ Capital Market.

    Patent Application

    Meanwhile, the clinical stage biopharmaceutical company has filed a patent application for the combination of AZIXA and Immune checkpoint inhibitors for the treatment of Cancer. The company on its filing says that the recent pre-clinical experiments have proved beyond doubt that the combination can cause improved tumor response.

    Chief executive officer, Dr. Daniel Teper, says that such combination treatments have the potential to augment response to immune checkpoint inhibitors. The executive expects the recent data to open up new potential strategic options, given that Azixa has already demonstrated pre-clinical trial and clinical activity in multiple tumor types.

    Expansion of Bertilimumab Phase II Trial

    Separately, Immune has confirmed the expansion of its Bertilimumab Phase II clinical trial to include six new clinical sites in the United States. The company has already received IRB approval for the use of the anti-eotaxin monoclonal antibody for the treatment of bullous pemphigoid.

    Bertilimumab bills itself as a first class anti-eotaxin able to block eotaxin-1, which is a key driver of the condition. Common in old people, the disease manifests itself with the blistering of the skin. There are currently about 60,000 people in the US and Europe struggling with the condition

    Some of the new sites where Immune Pharmaceuticals Inc (NASDAQ:IMNP) will carry out the trials include the, University Hospitals Cleveland Medical Center, Mount Sinai in New York, Duke University, the University of Iowa, the University of Buffalo, and the University of Utah.
    Mooi bijkoop momentje geweest bedoel je ;).

    Het artikel had ik gelezen, is al lang bekend en ze hebben nog tot jan. 2017.
    Tijd zat dus om die koers over de 1$ heen te jagen.

    Ze zullen toch wel wat informatie vrij hebben moeten geven aan nasdaq om die verlenging binnen te kunnen slepen?
  15. [verwijderd] 14 juli 2016 18:11
    quote:

    Omnius schreef op 14 juli 2016 09:33:

    Is er nieuws?
    In VS after hours + 10% en hier -10%.
    Nee alleen speculaties... Morgen deadline en er kan dus makkelijk pas maandag nieuws komen.
    Maar ook AH vandaag of morgen VB.

    Goed of slecht, er zit genoeg in de pijpleiding dus op dit nieuws alleen moet je niet gokken.

    Alhoewel dit nieuw de koers flink hoger kan zetten, en geeft weer wat lucht voor Immun.
  16. [verwijderd] 15 juli 2016 17:10
    Vele hadden gehoopt op nieuws gisteren of vandaag! Helaas is dit niet het geval en de koopjes jagers en daghandelaren schieten er weer uit. De deadline was tot vandaag dacht ik, echter wilt dit niet zeggen dat dit vandaag ook direct kenbaar gemaakt zal worden, althans de uitslag (wat ik voor de aandeelhouders als positief zie). Ik vermoed dat er begin volgende week wat kenbaar gemaakt zal worden wat de koers significant zal doen stijgen.

    Het gaat niet om een peulen schil maar om 160 miljoen investering.

    Ik zie dat de europose notering in het groen springt, wellicht verwachten zij maandag of nabeurs USA ook positiefs nieuws.
    IMNP notering USA in de min, maar ook hier verwacht ik eind van de dag een opwaartse druk en hopelijk in het groen eindigt.

    Greets en alvast een goed weekend
  20. [verwijderd] 18 juli 2016 22:10
    quote:

    Omnius schreef op 18 juli 2016 13:11:

    [...]

    op 14 stuks, ik geniet er nog maar even van totdat de beurs opengaat ;-)
    Haha precies, vals alarm. Maar al met al weer een mooie dag, mondje eerst dacht ik dat wordt slotje rond de 0.40.. Toen maar afgesloten en van het prachtige weer genoten en lekker gewerkt. Net een uurtje geleden gekeken en nondeju mooi slotje en dik volume.
766 Posts
Pagina: «« 1 2 3 4 5 6 ... 39 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
HEIJMANS KON 29,800 +2,20 +7,97%
AZERION 1,300 +0,05 +4,00%
AMG Critical Materials N.V. 15,200 +0,44 +2,98%
ArcelorMittal 23,990 +0,48 +2,04%
SIGNIFY NV 22,100 +0,38 +1,75%
ASR Nederland 44,940 +0,63 +1,42%
Aperam 28,220 +0,38 +1,36%
TKH 33,620 +0,42 +1,27%
Accsys 0,585 +0,01 +1,04%
Aegon 6,112 +0,06 +0,99%
PostNL 1,053 +0,01 +0,96%
ING 14,978 +0,14 +0,96%
SHELL PLC 31,055 +0,24 +0,78%
NN Group 45,300 +0,35 +0,78%
Kendrion 10,920 +0,08 +0,74%
RANDSTAD NV 41,600 +0,30 +0,73%
ACOMO 17,260 +0,12 +0,70%
RENEWI 7,430 +0,05 +0,68%
ASCX 1.209,03 +6,48 +0,54%
ALLFUNDS GROUP 5,345 +0,02 +0,47%
Flow Traders 21,200 +0,08 +0,38%
Air France-KLM 7,700 +0,02 +0,23%
Eurocommercial Properties 23,300 +0,05 +0,22%
BAM 4,170 +0,01 +0,19%
Sif Holding 12,240 +0,02 +0,16%
Wereldhave 14,100 +0,02 +0,14%
Fugro 16,130 +0,02 +0,12%
NSI 19,660 +0,02 +0,10%
DSM FIRMENICH AG 102,550 +0,05 +0,05%
UNILEVER PLC 54,400 +0,02 +0,04%
Brunel 8,590 0,00 0,00%
JDE PEET'S 18,500 0,00 0,00%
SBM Offshore 17,570 0,00 0,00%
TomTom 5,420 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO (RIGHT) 0,160 -0,22 -57,89%
EBUSCO HOLDING 1,266 -0,12 -8,86%
ASML 635,000 -36,60 -5,45%
Wolters Kluwer 151,650 -7,25 -4,56%
ASMI 507,600 -21,60 -4,08%
RELX 42,300 -1,48 -3,38%
Galapagos 25,540 -0,84 -3,18%
ADYEN NV 1.237,000 -39,80 -3,12%
Arcadis 62,950 -1,85 -2,85%
Pharming 0,715 -0,02 -2,79%
BESI 114,350 -2,90 -2,47%
Avantium 2,190 -0,06 -2,45%
B&S Group SA 4,300 -0,10 -2,27%
Corbion 21,840 -0,46 -2,06%
NX FILTRATION 4,540 -0,09 -2,05%
IMCD 142,150 -2,90 -2,00%
ForFarmers 3,350 -0,06 -1,90%
UMG 23,100 -0,44 -1,87%
INPOST 17,300 -0,27 -1,54%
Basic-Fit 22,820 -0,34 -1,47%
AEX 862,50 -11,98 -1,37%
THEON INTERNAT 8,980 -0,12 -1,32%
EXOR NV 93,600 -1,25 -1,32%
CM.COM 6,200 -0,08 -1,27%
Fagron 18,520 -0,20 -1,07%
Sligro 11,120 -0,12 -1,07%
JUST EAT TAKEAWAY 14,105 -0,14 -0,95%
PROSUS 37,750 -0,34 -0,88%
Heineken 71,340 -0,52 -0,72%
Ahold Delhaize 32,130 -0,22 -0,68%
FASTNED 22,050 -0,15 -0,68%
Van Lanschot Kempen NV 44,500 -0,30 -0,67%
Vastned 24,350 -0,15 -0,61%
Alfen N.V. 12,400 -0,07 -0,56%
AMX 870,21 -4,77 -0,55%
ABN AMRO BANK N.V. 14,790 -0,08 -0,54%
KPN 3,524 -0,02 -0,51%
WDP 20,620 -0,08 -0,39%
Nedap N.V. 53,400 -0,20 -0,37%
Akzo Nobel 55,680 -0,20 -0,36%
AALBERTS NV 35,220 -0,12 -0,34%
OCI 11,245 -0,03 -0,27%
Vopak 43,640 -0,10 -0,23%
Philips Koninklijke 24,560 -0,05 -0,20%
CTP 14,760 -0,02 -0,14%
vlag naam koers verschil relatief verschil
AEX 862,50 -11,98 -1,37%
AEX GR 3.382,99 -47,01 -1,37%
Germany40^ 19.239,20 -24,50 -0,13%
FTSE 100 8.063,61 -7,58 -0,09%
EURO50 4.796,06 0,00 0,00%
US30^ 43.483,80 0,00 0,00%
Nasd100^ 20.407,80 0,00 0,00%
US500^ 5.874,88 0,00 0,00%
Japan225^ 38.006,50 0,00 0,00%
VD-NEW 16,30 +0,17 +1,06%
#/^ Index indications calculated real time, zie disclaimer